Filing Analysis
Keros Therapeutics updated its corporate presentation to be used in meetings with investors and analysts. This is a routine disclosure intended for investor relations purposes.
📋 Key Facts
- Company updated its corporate presentation on August 3, 2026.
- The update is intended for use in meetings with investors, analysts, and other stakeholders.
- The presentation is available via the Company's website and attached as Exhibit 99.1.
Keros Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2026. The filing serves as a formal announcement of the company's recent earnings performance.
📋 Key Facts
- The filing reports on the quarter ended June 30, 2026.
- Financial results were announced via press release on August 3, 2026.
- The report was signed by CEO Jasbir Seehra, Ph.D.
Keros Therapeutics announced it will receive a $20 million development milestone payment from Takeda Pharmaceuticals. This follows the dosing of the first patient in the Phase 3 ELRiSE MDS clinical trial for elritercept.
📋 Key Facts
- Milestone payment amount: $20 million
- Partner company: Takeda Pharmaceuticals U.S.A., Inc.
- Trigger event: Dosing of the first patient in the ELRiSE MDS clinical trial
- Clinical trial details: Phase 3, multicenter, open-label, randomized trial comparing elritercept vs epoetin alfa for anemia due to MDS (very low, low, or intermediate risk).
Keros Therapeutics announced the resignation of CFO Keith Regnante, effective August 3, 2026. The company has appointed current Corporate Controller Annita Tanini as interim principal financial officer and principal accounting officer starting August 4, 2026.
🚩 Red Flags
- Unexpected departure of a key C-suite officer (CFO) during the reporting cycle.
- Reliance on an interim replacement for the CFO/CAO role while searching for a permanent successor.
📋 Key Facts
- CFO Keith Regnante resigned on July 17, 2026, to pursue other opportunities; effective date is August 3, 2026.
- Annita Tanini appointed as interim principal financial officer and principal accounting officer effective August 4, 2026.
- The company stated Regnante's resignation was voluntary and not due to disagreements regarding accounting practices or internal controls.
- Tanini will receive an annual base salary of $302,300 with a target cash bonus of 30%.
- Regnante is not entitled to additional severance beyond accrued salary and expense reimbursement.
Keros Therapeutics, Inc. announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors as a Class III director, effective July 1, 2026.
📋 Key Facts
- Dr. Anne Prener appointed as Class III Director effective July 1, 2026.
- Term expires at the Company's 2029 annual meeting of stockholders.
- Initial compensation includes a $150,000 stock option grant and a $150,000 RSU award (subject to vesting over 3 years).
- Annual compensation includes an option grant ($75,000), an RSU award ($75,000), and a $41,500 cash retainer.
- Equity grants are subject to ownership caps: initial grants capped at 0.075% of outstanding shares; annual grants capped at 0.0375%.
Keros Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended September 30, 2025. The filing serves as a formal announcement of the company's recent earnings release.
📋 Key Facts
- The filing was made on November 5, 2025.
- The report pertains to financial results for the quarter ended September 30, 2025.
- The primary content is a press release furnished as Exhibit 99.1.
Keros Therapeutics announced a massive capital return plan involving the repurchase of over 10 million shares from major stakeholders ADAR1 Capital and Pontifax Venture Capital at $17.75 per share. This transaction is accompanied by the resignation of two board members, Tomer Kariv and Ran Nussbaum.
🚩 Red Flags
- Departure of two board members (Tomer Kariv and Ran Nussbaum) coinciding with major capital restructuring.
- Significant concentration of control/influence shifts via large repurchases from specific venture entities.
- Repurchase agreements include long-term standstill restrictions (until 2028).
📋 Key Facts
- Repurchase of 10,176,595 shares from ADAR1 Parties (13.3% stake) and Pontifax Parties (11.8% stake).
- Aggregate repurchase price is approximately $181 million at $17.75 per share.
- Company intends to launch a tender offer to all stockholders by the end of October 2025 to return excess capital.
- Total planned return of excess capital to stockholders is $375.0 million.
- Tomer Kariv and Ran Nussbaum resigned from the Board of Directors effective October 15, 2025.
- Repurchase parties are subject to standstill restrictions and non-disparagement obligations until after the 2028 annual meeting.
Keros Therapeutics announced the presentation of Phase 1 clinical trial data for its KER-065 candidate in healthy male volunteers at the ASBMR 2025 Annual Meeting. The filing serves as a formal disclosure to accompany the press release containing these clinical updates.
📋 Key Facts
- Presented additional Phase 1 clinical trial data for KER-065 on September 6, 2025.
- Trial subjects were healthy male volunteers.
- Data was presented at the American Society of Bone and Mineral Research (ASBMR) 2025 Annual Meeting.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in two upcoming healthcare conferences: the Wells Fargo Healthcare Conference on September 4, 2025, and the H.C. Wainwright Global Investment Conference on September 9, 2025.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat at the 2025 Wells Fargo Healthcare Conference on Sept 4, 2025.
- CEO Jasbir Seehra to give a corporate presentation at the H.C. Wainwright 27th Annual Global Investment Conference on Sept 9, 2025.
Keros Therapeutics announced that the FDA has granted Orphan Drug designation for its candidate KER-065 to treat Duchenne muscular dystrophy. This is a regulatory milestone intended to provide incentives for the development of drugs for rare diseases.
📋 Key Facts
- FDA granted Orphan Drug designation for KER-065 on August 20, 2025.
- Target indication: Treatment of Duchenne muscular dystrophy.
- The announcement was made via a press release (Exhibit 99.1).
Keros Therapeutics announced a significant leadership reshuffle effective August 18, 2025, including the departure of the President and COO and a restructuring of the CEO's role. The company is simultaneously promoting internal talent to key executive positions.
🚩 Red Flags
- Multiple officer departures/changes in a single filing (Red Flag Escalator)
- Departure of the President and COO is often indicative of internal restructuring or strategic shifts.
- Significant severance obligations for departing executive (9 months salary + equity acceleration).
📋 Key Facts
- Christopher Rovaldi will cease serving as President and COO on August 18, 2025; he will provide up to 20 hours of consulting per month through November 18, 2025.
- Lorena Lerner, Ph.D., appointed as Chief Scientific Officer effective August 6, 2025.
- Esther Cho entered into a new employment agreement as Senior Vice President and General Counsel.
- Jasbir Seehra will transition from CEO/Chair to President and CEO; he will cease being Chair of the Board on August 18, 2025.
- Jean-Jacques Bienaimé appointed as new Chair of the Board effective August 18, 2025.
- Christopher Rovaldi's separation package includes 9 months of base salary severance and acceleration of 19,800 shares of common stock.
Keros Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2025. The filing serves as a formal announcement of the company's recent operational and financial performance.
📋 Key Facts
- The filing is related to Item 2.02: Results of Operations and Financial Condition.
- Financial results were announced for the quarter ended June 30, 2025.
- The announcement was made via a press release dated August 6, 2025 (Exhibit 99.1).
Keros Therapeutics announced the dosing of the first patient in its Phase 3 RENEW clinical trial for elritercept. This milestone event triggers a $10.0 million payment from Takeda Pharmaceuticals under their global license agreement.
📋 Key Facts
- First patient dosed in Phase 3 RENEW clinical trial for elritercept.
- Trial targets adults with transfusion-dependent anemia (very low, low, or intermediate risk MDS).
- Milestone achievement triggers a $10.0 million payment from Takeda Pharmaceuticals U.S.A., Inc.
- Filing date: July 17, 2025.
Keros Therapeutics announced the voluntary resignation of its Chief Medical Officer, Yung H. Chyung, M.D., effective August 1, 2025. The company has initiated a search for a successor.
🚩 Red Flags
- Departure of a key executive (CMO) in a clinical-stage biotech company can impact R&D momentum or clinical trial oversight.
📋 Key Facts
- Yung H. Chyung, M.D. resigned as Chief Medical Officer on July 9, 2025.
- The resignation is effective August 1, 2025.
- The departure is voluntary and not due to any disagreement with the Company.
- A search for a new CMO has commenced.
Keros Therapeutics held its 2025 Annual Meeting of Stockholders on June 4, 2025, resulting in the election of three directors and ratification of Deloitte & Touche LLP as auditors. Notably, the company also announced it has concluded a strategic review process intended to maximize stockholder value.
🚩 Red Flags
- Conclusion of 'strategic alternatives' review often implies potential sale, merger, or restructuring activity which introduces significant uncertainty for shareholders.
📋 Key Facts
- Annual Meeting held on June 4, 2025; quorum was present.
- Three nominees (Mary Ann Gray, Ran Nussbaum, and Alpna Seth) were elected to the Board of Directors until 2028.
- Stockholders approved Proposal 2: Ratification of Deloitte & Touche LLP as independent auditors for fiscal year ending Dec 31, 2025.
- Stockholders approved Proposal 3: Advisory vote on executive compensation (Say-on-Pay).
- On June 9, 2025, the company concluded a strategic review process to evaluate alternatives to maximize stockholder value.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference on June 9, 2025.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat presentation.
- Event: Goldman Sachs 46th Annual Global Healthcare Conference.
- Date of event: Monday, June 9, 2025, at 9:20 a.m. Eastern time.
Keros Therapeutics has announced a major reorganization involving a ~45% workforce reduction to reduce costs. This restructuring is accompanied by the release of topline data from its TROPOS clinical trial.
🚩 Red Flags
- Significant workforce reduction (45%) often indicates severe cash runway constraints or a pivot in corporate strategy.
- Large one-time restructuring charges ($3.6M total) impacting upcoming quarterly earnings.
- Multiple material events (restructuring + clinical data release) in a single filing.
📋 Key Facts
- Board approved a plan to reduce overall workforce by approximately 45%.
- One-time cash charges for severance and related reorganization costs estimated at ~$3.2 million, expected in Q2 2025.
- Committed up to ~$0.4 million in employee retention costs through Q4 2025.
- Reorganization is expected to be substantially complete by Q4 2025.
- Company released topline data from its TROPOS trial on May 29, 2025.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference on May 13, 2025. This is a routine regulatory disclosure regarding management's participation in an industry conference.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat presentation.
- Event: Bank of America 2025 Global Healthcare Conference.
- Date of event: Tuesday, May 13, 2025, at 8:00 p.m. ET.
Keros Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended March 31, 2025. The filing consists primarily of a press release announcing these results.
📋 Key Facts
- The company announced financial results for the quarter ended March 31, 2025.
- Results were released via press release on May 6, 2025.
- The filing is made pursuant to Item 2.02 of Form 8-K.
Keros Therapeutics entered into a Letter Agreement with Pontifax entities to resolve potential governance disputes. The agreement includes director nominations and standstill restrictions.
🚩 Red Flags
- Presence of 'standstill restrictions' often indicates a prior or potential proxy contest/activist investor involvement.
📋 Key Facts
- Agreement dated April 17, 2025, between Keros Therapeutics and Pontifax (Israel) IV, L.P., Pontifax (Cayman) IV, L.P., Pontifax (China) IV, L.P., and Pontifax Late Stage Fund L.P.
- The Company will nominate three current Board members—Mary Ann Gray, Ran Nussbaum, and Alpna Seth—for election at the 2025 Annual Meeting of Stockholders.
- Pontifax agreed to customary standstill restrictions effective until Dec 31, 2025, or the notice deadline for the 2026 Annual Meeting.
- The agreement includes mutual non-disparagement obligations.
Keros Therapeutics has implemented a shareholder rights plan (poison pill) in response to significant accumulations of common stock by investors seeking to influence company control. The plan was triggered after an individual investor disclosed a 11.2% stake as of April 6, 2025.
🚩 Red Flags
- Implementation of a 'poison pill' (Rights Plan) indicates an active defense against potential hostile takeover or activist investor intervention.
- The company explicitly states it believes shares do not reflect the Company’s intrinsic value, suggesting management-shareholder misalignment regarding valuation.
- Presence of an investor holding 11.2% of common stock creates immediate risk of a change in control or board composition.
📋 Key Facts
- Board declared a dividend of one right per share of common stock on April 9, 2025.
- Rights allow the purchase of 1/1,000th of a Series A Junior Participating Preferred Share at an exercise price of $165.00.
- The Rights Plan targets any person or group acquiring 10% (or 15% for passive institutional investors) of outstanding common stock without Board approval.
- An individual investor was identified as holding 11.2% of Keros' outstanding common stock as of April 6, 2025.
- The Rights Plan includes 'flip-in', 'exchange', and 'flip-over' provisions to protect against hostile takeovers.
- Record date for the rights distribution is set for April 24, 2025.
Keros Therapeutics announced initial topline results from its Phase 1 clinical trial of KER-065 in healthy volunteers. The company held a conference call and webcast to discuss these clinical developments with investors.
📋 Key Facts
- Announcement date: March 31, 2025
- Clinical stage: Phase 1 clinical trial results for KER-065
- Study population: Healthy volunteers
- Event type: Topline data release and investor presentation
Keros Therapeutics, Inc. has adopted Amended and Restated Bylaws following a periodic review of corporate governance matters. The changes primarily focus on updating procedural mechanics for stockholder director nominations and enhancing disclosure requirements.
📋 Key Facts
- Board approved and adopted Amended and Restated Bylaws effective March 5, 2025.
- Updates include new procedural mechanics for stockholder-submitted director nominations regarding Rule 14a-19 (universal proxy rules).
- New requirements for stockholders to provide representations regarding solicitation activities.
- Limits the number of nominees a stockholder may nominate to the number of directors being elected at that meeting.
- Enhanced disclosure requirements for nominees, including information on their associates and affiliates.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in two upcoming healthcare conferences: TD Cowen on March 3, 2025, and Leerink Partners on March 10, 2025.
📋 Key Facts
- CEO Jasbir Seehra to present at the TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 9:50 a.m. ET.
- CEO Jasbir Seehra to present at the Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. ET.
Keros Therapeutics issued an 8-K to furnish its quarterly and annual business highlights and financial results for the period ending December 31, 2024. The filing serves as a formal announcement of the company's recent operational performance.
📋 Key Facts
- Reporting period: Quarter and year ended December 31, 2024.
- Filing date: February 26, 2025.
- The filing includes a press release (Exhibit 99.1) detailing business highlights and financial results.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on February 6, 2025. This filing is primarily for Regulation FD disclosure purposes regarding upcoming non-public presentation details.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference.
- Event date: Thursday, February 6, 2025, at 10:00 a.m. ET.
- The filing includes an exhibit (99.1) containing the press release regarding this presentation.
Keros Therapeutics announced that its Exclusive License Agreement with Takeda Pharmaceuticals U.S.A., Inc. became effective on January 16, 2025, following the expiration of the HSR Act waiting period. This effectiveness triggers a significant upfront payment to Keros.
📋 Key Facts
- Exclusive License Agreement with Takeda Pharmaceuticals U.S.A., Inc. became effective on January 16, 2025.
- The agreement's effectiveness was contingent upon the expiration of the HSR Act waiting period.
- Takeda will make an upfront payment of $200.0 million to Keros Therapeutics.
Keros Therapeutics has voluntarily halted dosing in its Phase 2 TROPOS clinical trial for cibotercept (KER-012) due to safety concerns. The halt affects both the 1.5 mg/kg and placebo treatment arms following observations of pericardial effusion adverse events.
🚩 Red Flags
- Clinical trial halt in a lead candidate (cibotercept)
- Serious adverse events reported (pericardial effusion)
- Safety concerns affecting both active and placebo arms increases the risk of total program failure
📋 Key Facts
- Trial Name: TROPOS (Phase 2)
- Drug Candidate: cibotercept (KER-012) in combination with background therapy
- Indication: Pulmonary arterial hypertension
- Action: Voluntary halt of all dosing (including placebo arm)
- Reason for halt: Ongoing safety review due to new observations of pericardial effusion adverse events
- Date of event: January 15, 2025
Keros Therapeutics updated its corporate presentation to be used in meetings with investors and analysts. This is a routine disclosure under Regulation FD.
📋 Key Facts
- The Company updated its corporate presentation on January 10, 2025.
- The update is intended for use in meetings with investors, analysts, and other stakeholders.
- The presentation was made available via the Company's website as Exhibit 99.1.
Keros Therapeutics has voluntarily halted dosing in two treatment arms (3.0 mg/kg and 4.5 mg/kg) of its Phase 2 TROPOS clinical trial for cibotercept (KER-012). The decision follows a safety review triggered by unanticipated pericardial effusion adverse events.
🚩 Red Flags
- Clinical trial safety issue (pericardial effusion)
- Potential delay or termination of the lead drug candidate's development program
- Unanticipated adverse events in a Phase 2 setting
📋 Key Facts
- Trial: TROPOS (Phase 2 clinical trial)
- Drug: cibotercept (KER-012) in combination with background therapy
- Indication: Pulmonary arterial hypertension
- Action: Voluntary dosing halt for the 3.0 mg/kg and 4.5 mg/kg arms
- Reason: Safety review due to unanticipated pericardial effusion adverse events
- Date of event: December 12, 2024
Keros Therapeutics issued an 8-K to announce the release of additional data from its two ongoing Phase 2 clinical trials for elritercept (KER-050). The data was presented at the 66th American Society of Hematology Annual Meeting.
📋 Key Facts
- Company announced Phase 2 clinical trial data for elritercept (KER-050) on December 9, 2024.
- Trials involve patients with myelodysplastic syndromes (MDS) and myelofibrosis.
- Data presentation occurred at the 66th American Society of Hematology Annual Meeting.
Keros Therapeutics entered into a major exclusive license agreement with Takeda Pharmaceuticals for the global development and commercialization of elritercept (KER-050). The deal includes a significant $200 million upfront payment and substantial milestone/royalty potential.
🚩 Red Flags
- Takeda retains the right to terminate the agreement for convenience with notice.
📋 Key Facts
- Entered into an Exclusive License Agreement with Takeda Pharmaceuticals U.S.A., Inc. on December 3, 2024.
- Takeda receives exclusive rights to develop, manufacture, and commercialize elritercept (KER-050) globally (excluding mainland China, Hong Kong, and Macau).
- Upfront payment of $200.0 million due to Keros Therapeutics.
- Potential development/commercial milestones totaling up to $370.0 million.
- Potential sales milestones totaling up to $740.0 million.
- Royalty payments ranging from low double-digits to high teens based on annual net sales.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in two upcoming healthcare conferences: the Piper Sandler Annual Healthcare Conference on December 3, 2024, and the Evercore HealthConx Conference on December 4, 2024.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat at Piper Sandler 36th Annual Healthcare Conference on Dec 3, 2024.
- CEO Jasbir Seehra to participate in a fireside chat at the 7th Annual Evercore HealthConx Conference on Dec 4, 2024.
Keros Therapeutics, Inc. issued an 8-K to furnish its quarterly business highlights and financial results for the period ended September 30, 2024.
📋 Key Facts
- Report date: November 6, 2024
- Reporting period: Quarter ended September 30, 2024
- The filing is primarily a placeholder to furnish the press release containing financial results (Item 2.02).
Keros Therapeutics announced that CEO Jasbir Seehra will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference on November 13, 2024.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat presentation.
- Event: Guggenheim Healthcare Innovation Conference.
- Date of event: Wednesday, November 13, 2024, at 3:30 p.m. ET.
Keros Therapeutics announced the appointment of Dr. Yung H. Chyung as Chief Medical Officer, effective November 1, 2024, succeeding Simon Cooper, M.B.B.S.
📋 Key Facts
- Dr. Yung H. Chyung appointed as CMO, effective Nov 1, 2024.
- Succession replaces Simon Cooper, M.B.B.S.
- Annual base salary for Dr. Chyung is $510,000 with a 40% target discretionary bonus.
- Equity incentive includes an option to purchase up to 110,000 shares of common stock.
- Dr. Chyung previously served as EVP and CMO at Tourmaline Bio, Inc. and CMO at Scholar Rock Holding Corporation.
Keros Therapeutics announced the successful completion of patient enrollment for its Phase 2 TROPOS clinical trial. The trial evaluates cibotercept (KER-012) in patients with pulmonary arterial hypertension and exceeded its initial recruitment target.
📋 Key Facts
- Completed enrollment for the TROPOS Phase 2 clinical trial on September 30, 2024.
- Total of 113 patients enrolled, exceeding the original target of 90 patients.
- Trial evaluates cibotercept (KER-012) in combination with background therapy for pulmonary arterial hypertension.
- Topline data readout is expected in the second quarter of 2025.
Keros Therapeutics announced the completion of patient screening for its Phase 2 TROPOS clinical trial evaluating cibotercept (KER-012) for pulmonary arterial hypertension. The company expects to finish enrollment by late September 2024 and release topline data in Q2 2025.
📋 Key Facts
- Completed screening for the Phase 2 TROPOS trial on September 3, 2024.
- Trial evaluates cibotercept (KER-012) in combination with background therapy.
- Indication: Pulmonary arterial hypertension.
- Enrollment is expected to be complete by the end of September 2024.
- Topline data readout is anticipated in the second quarter of 2025.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in several upcoming healthcare conferences including Morgan Stanley, Wells Fargo, and Cantor Global Healthcare. The filing is a routine disclosure of non-material information under Regulation FD.
📋 Key Facts
- CEO Jasbir Seehra to attend Morgan Stanley 22nd Annual Global Healthcare Conference on Sept 4, 2024.
- CEO Jasbir Seehra to attend 2024 Wells Fargo Healthcare Conference on Sept 5, 2024.
- CEO Jasbir Seehra to attend 2024 Cantor Global Healthcare Conference on Sept 19, 2024.
Keros Therapeutics updated its corporate presentation for use in meetings with investors and analysts. This is a routine disclosure under Regulation FD to ensure all market participants have access to the same information.
📋 Key Facts
- The Company updated its corporate presentation on August 7, 2024.
- The update is intended for use in meetings with investors, analysts, and other parties.
- The presentation was made available via the Company's website as Exhibit 99.1.
Keros Therapeutics, Inc. filed an 8-K to furnish its quarterly financial results for the period ended June 30, 2024.
📋 Key Facts
- The filing is a standard announcement of quarterly earnings (Results of Operations and Financial Condition).
- Reporting period: Quarter ended June 30, 2024.
- Filing date: August 7, 2024.
Keros Therapeutics has filed a prospectus supplement to its existing Shelf Registration Statement to facilitate the issuance and sale of up to $350,000,000 in common stock via an 'at-the-market' (ATM) offering program.
🚩 Red Flags
- Potential for significant shareholder dilution due to the large scale of the $350M offering.
- ATM offerings can create downward pressure on the stock price during execution periods.
📋 Key Facts
- The company is increasing its capacity to sell shares under a Sales Agreement with Leerink Partners LLC.
- Total potential issuance amount: up to $350,000,000 of Common Stock.
- Sales will be conducted via an 'at the market' (ATM) offering on the Nasdaq Global Market.
- Leerink Partners will receive a commission of up to 3.0% of gross sales proceeds.
- The company is not obligated to make any sales under this agreement.
Keros Therapeutics announced a leadership restructuring effective July 1, 2024. CEO Jasbir Seehra will transition to Chair of the Board and step down as President, while Christopher Rovaldi will be promoted to President in addition to his current COO role.
🚩 Red Flags
- None identified; the filing explicitly states Dr. Seehra's resignation from the Presidency was not due to any disagreement with company operations, policies, or practices.
📋 Key Facts
- Jasbir Seehra to resign as President effective June 30, 2024; will become Chair of the Board on July 1, 2024.
- Christopher Rovaldi appointed President and COO effective July 1, 2024.
- Jean-Jacques Bienaimé appointed Lead Independent Director effective July 1, 2024.
- The company amended its Non-Employee Director Compensation Policy to include a $25,000 annual retainer for the Lead Independent Director.
Keros Therapeutics announced the presentation of clinical and preclinical data for its lead candidate, elritercept (KER-050), at the 29th Annual Hybrid Congress of the European Hematology Association. The data covers Phase 2 trials for myelodysplastic syndromes (MDS) and myelofibrosis (MF), alongside positive animal model results.
📋 Key Facts
- Presented Phase 2 clinical trial data for elritercept (KER-050) in MDS and MF patients at the EHA Congress.
- Presented preclinical data showing elritercept promoted erythropoiesis and mitigated anemia in an animal model of MF.
- Preclinical results indicated improved anemia associated with ruxolitinib therapy and improved muscle mass/function in animal models.
- The company held a conference call on June 17, 2024, to discuss pipeline updates.
Keros Therapeutics announced positive FDA feedback regarding the design and endpoints for its Phase 3 clinical trial of KER-050 in MDS patients. The company also provided updates on its Phase 2 enrollment timeline for KER-012.
📋 Key Facts
- FDA expressed general alignment on the design and endpoints for a proposed pivotal Phase 3 clinical trial for KER-050 (elritercept) in myelodysplastic syndromes (MDS).
- Phase 2 enrollment for KER-012 (cibotercept) in pulmonary arterial hypertension is expected to complete in Q4 2024.
- Company scheduled a corporate update conference call/webcast for June 17, 2024.
Keros Therapeutics announced that its President and CEO, Jasbir Seehra, will participate in a fireside chat at the Goldman Sachs 45th Annual Healthcare Conference on June 10, 2024.
📋 Key Facts
- CEO Jasbir Seehra to present at the Goldman Sachs 45th Annual Healthcare Conference.
- Presentation scheduled for Monday, June 10, 2024, at 2:40 p.m. ET.
- The filing is a Regulation FD disclosure regarding non-public information being shared via a public presentation.
Keros Therapeutics held its 2024 Annual Meeting of Stockholders on May 30, 2024. The meeting resulted in the election of three directors and the approval of several advisory proposals regarding auditor ratification and executive compensation.
📋 Key Facts
- Annual Meeting held on May 30, 2024.
- Three nominees elected to the Board: Jasbir Seehra, Ph.D., Nima Farzan, and Julius Knowles, serving until the 2027 Annual Meeting.
- Stockholders ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year ending Dec 31, 2024 (Proposal 2).
- Stockholders approved executive compensation on a non-binding advisory basis (Proposal 3).
- Stockholders voted in favor of an annual frequency for shareholder advisory votes on executive compensation (Proposal 4).
Keros Therapeutics, Inc. announced the appointment of Jean-Jacques Bienaimé to its Board of Directors and the Nominating Committee, effective June 1, 2024.
📋 Key Facts
- Jean-Jacques Bienaimé appointed as Class III director, term expiring at the 2026 annual meeting.
- Effective date of appointment: June 1, 2024.
- Appointed to serve on the Nominating and Corporate Governance Committee.
- Compensation includes an initial stock option grant for 20,000 shares vesting over three years.
- Annual compensation includes a $40,000 cash retainer and a $5,000 committee retainer.
- Eligible for annual grants of 10,000 shares per year.
Keros Therapeutics, Inc. issued an 8-K to furnish its quarterly business highlights and financial results for the period ending March 31, 2024.
📋 Key Facts
- The filing is a routine disclosure of quarterly financial results (Item 2.02).
- Reporting period: Quarter ended March 31, 2024.
- Date of report: May 8, 2024.
Keros Therapeutics announced that the FDA has granted Fast Track designation for its drug candidate KER-050 (elritercept) to treat anemia in patients with myelodysplastic syndromes. This regulatory milestone is intended to expedite the development and review process of the therapeutic.
📋 Key Facts
- FDA granted Fast Track designation for KER-050 (elritercept).
- Target indication: Anemia in adult patients with very low-, low-, or intermediate-risk myelodysplastic syndromes.
- Filing date: March 14, 2024.
Keros Therapeutics updated its corporate presentation to be used in meetings with investors and analysts. This is a routine regulatory filing under Regulation FD.
📋 Key Facts
- The company updated its corporate presentation on March 6, 2024.
- The update is intended for use in meetings with investors, analysts, and other stakeholders.
- The presentation is available via the Company's website and attached as Exhibit 99.1.
Keros Therapeutics announced that CEO Jasbir Seehra will participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference on March 12, 2024. This is a routine regulatory disclosure under Item 7.01 regarding Regulation FD.
📋 Key Facts
- CEO Jasbir Seehra to participate in a fireside chat at the Leerink Partners 2024 Global Biopharma Conference.
- Event date: Tuesday, March 12, 2024, at 3:00 p.m. ET.
- The filing is furnished under Item 7.01 (Regulation FD Disclosure) and is not considered 'filed' for purposes of Section 18 liability.
Keros Therapeutics announced the voluntary resignation of its Chief Medical Officer, Simon Cooper, effective March 12, 2024. The company has initiated a search for a successor.
🚩 Red Flags
- Departure of a key executive (Chief Medical Officer) in a clinical-stage biotech company can disrupt clinical development timelines or strategy.
📋 Key Facts
- Simon Cooper, M.B.B.S., resigned as Chief Medical Officer on February 29, 2024.
- The resignation is effective March 12, 2024.
- The departure is voluntary and not due to any disagreement with the Company.
- The Company has commenced a search for a new CMO.
Keros Therapeutics issued an 8-K to furnish its quarterly and annual business highlights and financial results for the period ended December 31, 2023. The filing serves as a formal announcement of their recent operational performance.
📋 Key Facts
- Reporting period: Quarter and year ended December 31, 2023.
- Filing date: February 28, 2024.
- The company issued a press release (Exhibit 99.1) containing business highlights and financial results.
Keros Therapeutics announced the closing of an underwritten public offering of common stock. The company successfully raised significant capital, significantly extending its cash runway into 2027.
📋 Key Facts
- Closed underwritten public offering of 4,025,000 shares at $40.00 per share on January 8, 2024.
- Underwriters fully exercised their option to purchase an additional 525,000 shares.
- Net proceeds from the Offering (before expenses) were approximately $151.3 million.
- Combined with existing cash and previous ATM sales ($68.5M), the company expects to fund operations into 2027.
Keros Therapeutics entered into an underwriting agreement to offer 3.5 million shares of common stock at $40.00 per share. The company expects to net approximately $131.2 million to fund clinical trials and R&D activities.
🚩 Red Flags
- Equity dilution: Issuance of 3.5 million new shares will dilute existing shareholders.
📋 Key Facts
- Offering size: 3,500,000 shares of common stock.
- Offering price: $40.00 per share.
- Estimated net proceeds: Approximately $131.2 million.
- Underwriters include Goldman Sachs & Co. LLC, Leerink Partners LLC, Piper Sandler & Co., and Truist Securities, Inc.
- Expected closing date: January 8, 2024.
- Use of proceeds includes advancing KER-050 (Phase 2/3), KER-012 (Phase 2), and KER-065 (Phase 1) clinical programs.
Keros Therapeutics updated its corporate presentation and announced the commencement of a Phase 1 clinical trial for KER-065, a novel ligand trap targeting obesity.
📋 Key Facts
- Updated corporate presentation released on January 3, 2024 (Exhibit 99.1).
- Announced development of KER-065, a ligand trap designed to inhibit TGF-ß ligands (including myostatin/GDF8 and activin A) for obesity treatment.
- Commenced a randomized, double-blind, placebo-controlled, two-part Phase 1 clinical trial evaluating single and multiple ascending doses of KER-065 in healthy volunteers.